Exact Sciences (EXAS) PT Raised to $85 at Piper Sandler

Piper Sandler analyst David Westenberg raised the price target on Exact Sciences (NASDAQ: EXAS) to $85.00 (from $75.00) while maintaining a Overweight rating.

The analyst commented, "We see EXAS as having significant operating leverage even if Cologuard simply grows at consensus numbers. Currently, Cologuard Plus is still not in consensus numbers and represents further growth and a margin expansion opportunity. We don't believe EXAS' blood test will read out with breakthrough results, but assuming it's in a similar zip code to Guardant Shield, it would represent a defensive opportunity where investors could stop looking at EXAS as having an impaired terminal value. The company will report its algorithm study Monday, and with positive results, we think investors can resume their focus on operating leverage. We reiterate OW, call EXAS our top idea, and
update our PT to $85 (from $75)."

You May Also Be Interested In

• Fiserv (FISV) PT Lowered to $60 at Freedom Broker
• Cantor Fitzgerald Reiterates Overweight Rating on Applied Materials (AMAT)
• Freedom Broker Upgrades Lifeway Foods (LWAY) to Buy